Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Heavy metal or compound thereof
Reexamination Certificate
2005-02-15
2005-02-15
Pryor, Alton (Department: 1616)
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Heavy metal or compound thereof
Reexamination Certificate
active
06855339
ABSTRACT:
The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
REFERENCES:
patent: 132275 (1872-10-01), Gettings
patent: 232807 (1880-10-01), Dennett
patent: 3700498 (1972-10-01), Kanazawa et al.
patent: 4497780 (1985-02-01), Barin et al.
patent: 5759837 (1998-06-01), Kuhajda et al.
patent: 6720011 (2004-04-01), Zhang
patent: 6723351 (2004-04-01), Warrell et al.
patent: 6733792 (2004-05-01), Lu
patent: 6770304 (2004-08-01), Warrell et al.
patent: 20020013371 (2002-01-01), Warrell et al.
patent: 20020183385 (2002-12-01), Ellison et al.
patent: 20030099719 (2003-05-01), Warrell et al.
patent: 1061908 (1992-06-01), None
patent: 1079391 (1993-12-01), None
patent: 1081104 (1994-01-01), None
patent: 1119113 (1996-03-01), None
patent: 1121807 (1996-05-01), None
patent: 1122700 (1996-05-01), None
patent: 1131037 (1996-09-01), None
patent: 1133725 (1996-10-01), None
patent: 43 17 331 (1994-12-01), None
patent: 2 539 993 (1994-03-01), None
patent: 51-88620 (1976-03-01), None
patent: 11667 (1997-06-01), None
patent: WO-9402103 (1994-02-01), None
patent: WO-9402108 (1994-02-01), None
patent: WO-9501789 (1995-01-01), None
patent: WO-9522336 (1995-08-01), None
Chen et al, In vitro studies on cellular and moleccular mechanisms of arsenic trioxide in the treatment of leukemia, 1996, vol., 88 No. 3, pp. 1052-1061 (ABS).*
Cutler et al., Article IV, American Journal of the Medical Sciences, pp. 74-84, Jan. 1878.
Forkner et al., “Arsenic as a therapeutic agent in chronic myelogeneous leukemia”, Jour. A.M.A. 97(10):3-5, 1931.
Stephens, et al., “The therapeutic effect of solution of potassium arsenite in chronic myelogenous leukemia”, University of Rochester, pp. 1488-1502, 1936.
Neubauer, “Arsenical cancer: a review”, Arsenic Committee of the Medical Research Council, pp. 192-251, 1947.
Shibuya, “Studies on experimental arsenious acid poisoning”, Tokyo Jikeikai Ika Daigaku Zasshi, 86(4):653-675, 1971.
Pories et al., “Trace elements that act to inhibit neoplastic growth”, Annals of New York Academy of Sciences, 199:265-273, Jun. 25, 1972.
Monfardini et al., “Survival in chronic myelogenous leukemia: influence of treatment and extent of disease at diagnosis”, Cancer 31: 492-501, 1973.
Kerkvliet et al., “Immunotoxicology Studies of Sodium Arsenate-effects of Exposure on Tumor Growth and Cell-mediated Tumor Immunity”, J. Environmental, vol. 4, pp. 65-79, 1980.
Ishinishi, et al., “Study on Chronic Toxicity of Arsenic Trioxide in Rats with Special Reference to the Liver Damages”, Fukuok Acta Medicine, 71:27, 1980.
Arsenic, Environmental Health Criteria, 18, Geneva: WHO, 1981.
Cuzick et al., “Medicinal Arsenic and Internal Malignancies”, Br. J. Cancer, 45:904-911, 1982.
Qi and Bi, Method for Removing As203from Realgar, Chung Yao Tung Pao, 8(5):21-22, 1983.
Kasper et al., “Hepatic Angiosarcoma and Brochioloalveolar Carcinoma Induced by Fowler's Solution”, JAMA 252(24):3407-3408, 1984.
Zhang et al., “Clinical Study on the Treatment of Acute Promelocytic Leukemia with Ai Ling #1”, J. of Traditional Chinese and Western Medicine, vol. 4, No. 1, p. 19, 1984.
Pershagen et al., “On the Pulmonary Tumorigenicity of Arsenic Trisulfide and Calcium Arsenate in Hamsters”, Cancer Letters, 27:99-104, 1985.
Shimotsuura et al., “Studies on the Antineoplastic Actions of As2O3”, Shikwa Gakuho, 86:1237-1253, 1986.
Yamamoto et al., “Tumorigenicity of Inorganic Arsenic Compounds Following Intratracheal Instillations to the Lungs of Hamsters”, Int. J. Cancer 40:220-223, 1987.
Lee et al., “Induction of Gene Amplification by Arsenic”, Science, 241: 79-81, 1988.
Li et al., “Traditional Chinese and Western Medicine in the Treatment of 27 Patients with Malignant Lymphoma”, Chinese J. Oncology, 10:61-52, 1988.
Sun, Hongde et al., “32 Cases of Acute Early Granulocytic Leukemia Treated with AI-Ling No. 1 in Combination with Chinese Medical Practice of Pattern Identification”, Zhongguo Zhongxiyi Jiehe Zazhi, vol. 12(3), 170-171, 1992.
Peng, Zhang et al., “Treatment of Acute Promyelocyte Leukemia with Intraveneous Arsenic Trioxide”, Chinese Journal of Hematology, vol. 17, Translation, Feb. 1996.
Arsen (III)-Sulfid As2S2, Gmelin's Arsenic, 8.sup.th Edition, 17:422-433, 1952.
Diarsendisulfid As2S2, Gmelin's Arsenic, 8.sup.th Edition, 17:417-422, 1952.
Goodman & Gilman's “The Pharmacological Basis of Therapeutics”, Ninth Edition, McGraw-Hill, Health Professions Division, pp. 1659-1662.
“Inorganic Arsenci Compounds Other Than Arsine Health and Safety Guide”, Health and Safety Guide No. 70, WHO, Geneva 1992.
“Xionghyuang, Realgar”, Chinese Pharmacopia (I), Guangdong Science and Technology Publishing House, China, pp. 298-299, 1995.
Akao et al., “Arsenic Induces Apoptosis in B-cell Leukemic Cell Lines in Vitro: Activation of Caspases and Down-regulation of Bcl-2 Protein”, British J of Hematology, 102, 1055-1060, 1998 ©Blackwell Science Ltd.
Andre et al., “The PML and PML/RARα. Domains: From Autoimmunity to Molecular Oncology and From Retinoic Acid to Arsenic”, Experimental Cell Research, 229:253-260, 1996 ©Academic Press, Inc. 1996.
Chemical Abstract, 63-Pharmaceuticals 11:317, 111:219272j and 111:219276p, 1987-1991.
Chen et al., “In Vitro Studies on Cellular and Molecular Mechanisms of Arsenic Trioxide (As2O3) in the Treatment of Acute Promyelocytic Leukemia: As2O3induces NB4Cell Apoptosis with Down Regulation of Bcl-2 Expression and Modulation of PML-RARα/PML proteins”, Blood 88(3): 1052-1061, Aug. 1996, ©American Society of Hematology 1996.
Chen et al., “Use of Arsenic Trioxide (As2O3) in the Treatment of Acute Promyelocytic Leukemia (APL):I. As2O3Exerts Dose-Dependent Dual Effects on APL Cells”, Blood 89(9):3345-3353, 1997 ©The American Society of Hematology 1997.
Chung et al., “Influence for Carcinoma Cell and Lymphatic Cell of Acetyl Arsonate”, Yakhak Hoeji 40(5):599-607, 1996 (Abstract Only).
De The “L'oxyde d'arsenic: apres l'acide retinoique, un nouveau traitement cible dela leucemie aigue promyelocytaire” Medecine/Sciences, 13:867-71, 1997.
Dictionary of Inorganic Compounds, vol. 1, Ac-C10,IC-0006667-IC-000671 (1992).
Flamigni et al, “Effect of Sodium Arsenite on the Induction and Turnover of Ornithine Decarboxylase Activity in Erythroleukemia Cells”, Cell Biochemistry and Function 7:213-217, 1989.
Fluka, 1995/96 Catalog: 152-153.
Germolec et al., “Arsenic Induces Overexpression of Growth Factors in Human Keratinocytes”, Toxicology and Applied Pharmacology, 141:301-318, 1996 ©Academic Press, Inc., 1996.
Huang et al., 1995, “The Clinical Study of QINGDAI Tablet for Treating Acute Promyelocytic Leukemia”, China Magazine of Hematology, 16(1):26.
Konig et al., “Comparative Activity of Melarsoprol and Arsenic Trioxide in Chronic B-Cell Leukemia Lines”, Blood 90(2):562-570, 1997. ©The American Society of Hematology 1997.
Kwong et al., “Delicious Poison: Arsenic Trioxide for the Treatment of Leukemia”, Blood 89:3487-8, 1997.
Lu et al., “Effective treatment of AML-M3 (APL) and Their Remission Maintenance with Realgar: A Pilot Clinical and Laboratory Study on 38 Patients”, Blood, 90 (10 Suppl. 1, part 1):416A, #1849, 1997.
Lu et al., “Study of Reaglar in the Treatment of Acute Promyelocytic Leukemia (APL)-a pilot clinical and laboratory study on 32 Patients”, China-Korea Medical Conference '97 , 1997.
Mervis, “Ancient Remedy Performs New Tricks”, Science 273:578, 1996.
Neubauer
Gabrilove Janice L.
Pandolfi Pier Paolo
Warrell, Jr. Raymond P.
Lerner David Littenberg Krumholz & Mentlik LLP
Memorial Sloan-Kettering Cancer Center
Pryor Alton
LandOfFree
Process for producing arsenic trioxide formulations and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for producing arsenic trioxide formulations and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for producing arsenic trioxide formulations and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3507815